Geriatric high-grade soft tissue sarcoma (G-HG STS): An analysis of 116 patients (pts) evaluating prognostic factors and clinical outcomes stratified by histology.

Authors

null

Richard Hong Hui Quek

National Cancer Centre, Singapore, Singapore

Richard Hong Hui Quek , Mohamad Farid Rin Harunal Rashid , Summer Pan , Mann Hong Tan , Leon Siang Shen Foo , Kesavan Sittampalam , Alisa Sairi , Kiraely Adam , Widayana Hanafi , Soon Thye Lim , Kevin Tay , Lay-Tin Soh , Francis Chin , Melissa Teo , Donald Poon

Organizations

National Cancer Centre, Singapore, Singapore, Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore, National Cancer Centre Singapore, Singapore, Singapore, Singapore General Hospital, Singapore, Singapore, Singapore General Hospital, Department of Pathology, Singapore, Singapore, National Cancer Centre Singapore, SIngapore, Singapore, Raffles Cancer Centre, Raffles Hospital, Singapore, Singapore

Research Funding

No funding sources reported
Background: STS in geriatric pts is not well studied. We evaluated prognostic factors and clinical outcomes in elderly pts with HG STS. Methods: Single centre retrospective study. G-HG STS pts defined as age > 65 yrs seen in our centre from 2002 - 2011 with complete medical records were identified. Charlson age-comorbidity score was assessed for each pt. Results: 116 pts from 4 most common HG STS histo-types representing 69% of pts in the geriatric STS cohort were analysed; leiomyosarcoma (LMS, 14%), non well-differentiated liposarcoma (nWD-LPS, 9%), angiosarcoma (AS, 30%), and undifferentiated pleomorphic sarcoma (UPS, 47%). Median age was 72 yrs, 81% presented with localised disease; of 78% of these localised pts who had curative surgery, 49% received adjuvant therapy, of whom 92% had radiotherapy (RT) only. AS arises more commonly from the head/neck region (p<0.001) and fewer receive curative surgery (p=0.006). In 43 pts who had metastases either at diagnosis or relapse, 33% received first-line palliative chemotherapy with a response rate of 27% in evaluable pts. At a median follow-up of 15.8 mths, overall survival (OS) for the entire cohort was 25.1 mths, 30.5 vs 3.9 mths in pts presenting with localised vs metastatic disease respectively (p<0.0001). In pts who had curative surgery for localised disease, overall relapse-free survival (RFS) was 17.7mths; 26.8 mths vs 16.0 mths vs 7.3 mths vs 12.5 mths in LMS, nWD-LPS, AS and UPS respectively. In univariate analysis, adjuvant RT, non-head/neck primary and sarcoma subtype were associated with improved RFS. In multivariate analysis, adjuvant RT (p<0.001), sarcoma subtypes AS (p=0.011) and UPS (0.012) vs LMS remained significant. In pts with metastatic HG STS either at diagnosis or relapse, overall median OS was 5.9 mths; 5.9 mths (LMS), 30.5 mths (nWD-LPS), 6.4 mths (AS) and 4.3 mths (UPS). In univariate analysis, presence of bone metastases was significantly associated with inferior OS (p=0.0029). Charlson score did not correlate with RFS or OS. Conclusions: Prognosis of G-HG STS appears poor particularly in AS and UPS. Adjuvant RT improves outcomes in this group of pts and should not be omitted based on age alone.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Citation

J Clin Oncol 30, 2012 (suppl; abstr 10051)

DOI

10.1200/jco.2012.30.15_suppl.10051

Abstract #

10051

Poster Bd #

48D

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Prognostic factors for GEM + nab-PTX combination therapy in elderly patients with pancreatic cancer.

First Author: Kazuki Watabe

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Neoadjuvant chemoradiation in elderly Irish patients with esophageal cancer: A review of the clinical outcomes and toxicity.

First Author: Ronan Andrew Mc Laughlin

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Relevance of adjuvant chemotherapy in elderly patients with low rectal tumors.

First Author: Sola Adeleke